Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

L. G. Estévez, E. García, M. Hidalgo

Research output: Contribution to journalReview articlepeer-review

Abstract

Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)541-549
Number of pages9
JournalClinical and Translational Oncology
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2016

Keywords

  • Breast cancer
  • Buparlisib
  • PI3K inhibitor
  • PI3KCA
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma'. Together they form a unique fingerprint.

Cite this